Speciality: Pulmonary Medicine
Description:
A warm welcome to all the medical professionals in this interesting session on biologics target severe allergic asthma, improving lung function and reducing exacerbations.
Biologics are a breakthrough in treating severe allergic asthma, targeting specific immune pathways to reduce inflammation and improve symptoms. In individuals with severe asthma not well-controlled by standard medications, biologics offer a targeted approach, often by blocking key inflammatory molecules like interleukins or immunoglobulin E (IgE). These medications, typically monoclonal antibodies, help reduce asthma exacerbations, improve lung function, and enhance quality of life.
Biologics are especially effective in eosinophilic asthma subtypes, where elevated eosinophil levels indicate a more robust inflammatory response. Treatment selection is guided by patient-specific factors like biomarker profiles and treatment response. While biologics have revolutionized asthma management, their high cost and route of administration (usually via injection or infusion) are important considerations.
However, for individuals with severe allergic asthma unresponsive to traditional therapies, biologics offer hope for better symptom control and improved quality of life.
Therefore, get an overall knowledge on biologics target severe allergic asthma, improving lung function and reducing exacerbations.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation